Genome-Wide Study of Response to Platinum, Taxane, and Combination Therapy in Ovarian Cancer: In vitro Phenotypes, Inherited Variation, and Disease Recurrence

Fridley, Brooke L.; Ghosh, Taraswi Mitra; Wang, Alice; Rama, Raghavan; Dai, Junqiang; Goode, Ellen L.; Lamba, Jatinder K.

doi:10.3389/fgene.2016.00037

Cited by 24 publications

(19 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, the anti‐apoptotic function and invasion ability of MB cells, rather than cell proliferation, were increased after SNCA siRNA transfection, but decreased after overexpression of the gene, indicating the potential tumor suppressor function of SNCA in MB. Expression of SNCA was observed to have a close relationship with SNCAIP in MB (Figure ), which has been reported to be related with various tumors . Future study will be required to understand the mechanism of the synergetic effect between SNCA and SNCAIP on MB tumor invasion as well as apoptosis in vitro and in vivo.…”

Section: Discussionmentioning

confidence: 75%

SNCA, a novel biomarker for Group 4 medulloblastomas, can inhibit tumor invasion and induce apoptosis

Jiang

et al. 2018

Cancer Science

View full text Add to dashboard Cite

Medulloblastoma (MB) is the most common malignant brain tumor in childhood. It contains at least four distinct molecular subgroups. The aim of this study is to explore novel diagnostic and potential therapeutic markers within each subgroup of MB, in particular within Group 4, the largest subgroup, to facilitate diagnosis together with gene therapy. One hundred and six MB samples were examined. Tumor subtype was evaluated with the NanoString assay. Several novel tumor related genes were shown to have high subgroup sensitivity and specificity, including PDGFRA,FGFR1, and ALK in the WNT group, CCND1 in the SHH group, and α‐synuclein (SNCA) in Group 4. Knockdown and overexpression assays of SNCA revealed the ability of this gene to inhibit tumor invasion and induce apoptosis. Methylation‐specific PCR and pyrosequencing analysis showed that epigenetic mechanisms, rather than DNA hypermethylation, might play the key role in the regulation of SNCA expression in MB tumors. In conclusion, we identify SNCA as a novel diagnostic biomarker for Group 4 MB. Some other subgroup signature genes have also been found as candidate therapeutic targets for this tumor.

show abstract

Section: Discussionmentioning

confidence: 75%

SNCA, a novel biomarker for Group 4 medulloblastomas, can inhibit tumor invasion and induce apoptosis

Jiang

et al. 2018

Cancer Science

View full text Add to dashboard Cite

show abstract

“…For example, a FRAS1‐knockdown in a lung cancer cell line inactivates the FAK pathway and suppresses tumor invasion and migration . FRAS1 is involved with resistance of ovarian cancer to carboplatin and the resistance of renal cancer to sunitinib . Furthermore, analysis of a xenograft model of human endometrial cancer concluded that FRAS1 is a promising diagnostic marker .…”

Section: Discussionmentioning

confidence: 99%

Fraser extracellular matrix complex subunit 1 promotes liver metastasis of gastric cancer

Umeda

Kanda

Miwa

et al. 2019

Intl Journal of Cancer

View full text Add to dashboard Cite

Liver metastasis is often fatal in patients with gastric cancer, therefore, we aimed to identify genes associated with the mechanisms of liver metastasis of gastric cancer (GC) and to investigate their potential to predict recurrence and to serve as targets of therapy. Recurrence pattern‐specific transcriptome analysis was performed to identify liver metastasis‐associated genes. A stable knockout cell line was generated to investigate metabolic pathways that contribute to the malignant phenotype in vitro and vivo. Three hundred GC patients were analyzed to demonstrate an association between gene expression levels and clinicopathological parameters. As a results extracellular matrix complex subunit 1 (FRAS1) was identified as a liver metastasis‐associated gene. Pathway analysis revealed that FRAS1 expression was significantly correlated with the expression of genes encoding TGFB1, MAP1B, AHNAK, BMP2, MUC1, BIRC5, MET, CDH1, RB1 and MKI67. FRAS1 expression was associated with the activation of the EGFR and PI3K signaling pathways. The proliferation ability of FRAS1 knockout cell line (FRAS1‐KO) was inhibited compared to that of the parent cell line through caspase activity increment and cell cycle alteration. FRAS1‐KO cells exhibited increased responsiveness to oxygen stress and diminished stemness, invasiveness, and migration. Mouse models of GC revealed decreases in tumor formation and generation of metastasis by FRAS1‐KO cells. Moreover, the cumulative liver recurrence rate was significantly increased in patients with GC with high FRAS1 expression levels. We concluded that FRAS1 contributes to the malignant phenotype of GC, especially liver metastasis, and may therefore serve as a predictive marker or a target for treating liver metastasis.

show abstract

“…In the current study, among these four lncRNA biomarkers, a genome-wide association study (GWAS) showed that MGC32805 may be involved in paclitaxel in vitro drug response phenotypes, which are moderately associated with the time to epithelial ovarian cancer recurrence [16] . Another GWAS revealed that the SNP rs146949893 in RP1-35C21.2 may be related to height [17] .…”

Section: Discussionmentioning

confidence: 85%

Identification of Potential Prognostic Biomarkers for Tongue Squamous Cell Carcinoma

Zhang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Tongue squamous cell carcinoma (TSCC) is one of the most common types of oral cancer and has a poor prognosis owing to a limited understanding of the pathogenesis mechanisms. The purpose of this study was to explore and identify potential biomarkers in TSCC by integrated bioinformatics analysis. Methods: The RNA sequencing data and clinical characteristics of TSCC patients were downloaded from The Cancer Genome Atlas (TCGA), and then differentially expressed RNAs (DERNAs), including differentially expressed long noncoding RNAs (DElncRNAs) and differentially expressed messenger RNAs (DEmRNAs), were identified in TSCC by bioinformatics analysis. Subsequently, Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and Hallmark pathway analyses were used to analyze the DERNAs. Using univariate and multivariate Cox regression analyses, four-lncRNA and two-mRNA signatures were developed and used for predicting survival in TSCC patients. We established a risk model to predict the overall survival (OS) of TSCC patients based on the DERNAs with Kaplan–Meier analysis and the log-rank p test. Furthermore, weighted gene coexpression network analysis (WGCNA) was performed in Cytoscape, and a protein-protein interaction (PPI) network was established in the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database. Results: A total of 2,006 DEmRNAs and 1,001 DElncRNAs were found to be dysregulated in TSCC. A total of 417 DERNAs were used to construct the coexpression network, and the PPI network included 103 DEmRNAs. Univariate regression analysis of the DERNAs revealed 51 DElncRNAs and 90 DEmRNAs that were associated with OS in TSCC patients. Multivariate Cox regression analysis demonstrated that four of those lncRNAs (MGC32805, RP1-35C21.2, RP11-108K3.1, RP11-109M17.2) and two mRNAs (CA9, GTSF1L) had significant prognostic value, and their cumulative risk score indicated that these four-lncRNA and two-mRNA signatures independently predicted OS in TSCC patients. Conclusions: The current findings provide novel insights into the molecular mechanisms of TSCC and identify four lncRNAs and two mRNAs that are potential biomarkers that may be independent prognostic signatures for TSCC diagnosis and treatment.

show abstract

Genome-Wide Study of Response to Platinum, Taxane, and Combination Therapy in Ovarian Cancer: In vitro Phenotypes, Inherited Variation, and Disease Recurrence

Cited by 24 publications

References 47 publications

SNCA, a novel biomarker for Group 4 medulloblastomas, can inhibit tumor invasion and induce apoptosis

SNCA, a novel biomarker for Group 4 medulloblastomas, can inhibit tumor invasion and induce apoptosis

Fraser extracellular matrix complex subunit 1 promotes liver metastasis of gastric cancer

Identification of Potential Prognostic Biomarkers for Tongue Squamous Cell Carcinoma

Contact Info

Product

Resources

About